ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1065

Acute Myocardial Infarction Variation Among U.S. Medicaid Recipients With Systemic Lupus Erythematosus By Race and Ethnicity, 2000-2006

Medha Barbhaiya1, Candace H. Feldman1, Jessica M. Franklin2, Jun Liu3, Joanne M. Foody4, Michael A. Fischer2, Daniel H. Solomon1 and Karen H. Costenbader1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 3Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, 4Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: race/ethnicity and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: SLE patients have elevated rates of acute myocardial infarctions (MI), but the sociodemographic groups that are most affected have not been well studied. We examined acute MI rates among SLE patients in different sociodemographic groups enrolled in Medicaid, the program providing medical insurance to low income individuals in the U.S., from 2000 to 2006.

Methods: From Medicaid Analytic eXtract (MAX) data, containing all billing claims from 2000-2006 for Medicaid patients from 47 U.S. states and Washington, D.C., we identified patients aged 18-65 with prevalent SLE (>3 SLE International Classification of Disease, 9threvision, [ICD-9 codes] of 710.0, >30 days apart). Demographic data included age, sex, race/ethnicity, U.S. region of residence (Northeast, Midwest, South or West) and calendar year. Within MAX inpatient claims files, ICD-9 code were used to identify all inpatient diagnoses for acute MI (ICD-9 codes 410.XX). CVD event incidence rates per 1,000 person-years with 95% CIs for patients with SLE in each sociodemographic group were calculated. We also performed Cox regression models stratified by sex and race/ethnicity, and adjusting for age, calendar year and U.S. region, to calculate hazards ratios for acute MIs in this population.

Results: We identified 43,351 patients with prevalent SLE. 40,417 (93%) were female. Racial and ethnic breakdown was: African American (35%), White (35%), Hispanic (14%), Asian (3%), and Native American (1%). The incidence rate for acute MI was 6.26 (95%CI 5.86, 6.69) per 1,000 person-years for the entire SLE population. Incidence rates were higher among males than females for all race/ethnicities (except for Native Americans for whom there were no events among males). (Table) Among women with SLE, Asians and Hispanics had the lowest incidence rates for acute MIs. Among males, incidence rates were also highest among White and African American patients, and lower in Asian and Hispanic SLE patients. Adjusted hazard ratios for acute MIs were significantly lower among Hispanic women compared to White women; however, they were not statistically lower among Asian women compared to White women. Although not statistically significant, lower hazard ratios for acute MIs were found in all non-White groups of men with SLE as well.

Conclusion: We found marked sex and race/ethnicity-specific variation in acute MI incidence rates and adjusted hazards ratios among Medicaid patients with SLE. The rates were higher among Whites and African American individuals. Further research is necessary to understand whether there is variation in acute MI prevention, cardiac risk factors, presentation, diagnosis and management among SLE patients in different sociodemographic groups. 

 

Table. Incidence Rates and Adjusted Hazards Ratios for Hospitalizations for Acute Myocardial Infarctions among Medicaid patients with SLE in the U.S. by Race and Ethnicity, 2000-2006 

SLE Patients in Medicaid*

Total Individuals

N events

IR**

95% CI

Person-years

HR***

95% CI 

Females

White

14,010

296

6.34

5.66 – 7.11

46,672

1.0 (ref.)

–

African American

14,195

277

5.93

5.27 – 6.67

46,702

1.05

0.89 – 1.24

Asian

1,095

****

2.81

1.51 – 5.22

3,558

0.68

0.36 – 1.28

Hispanic

5,887

63

3.14

2.45 – 4.02

20,045

0.66

0.50 – 0.87

Native American

519

11

6.65

3.68 – 12.01

1,654

1.21

0.66 – 2.22

Other/ Multiple

2,667

72

7.71

6.12 – 9.71

9,344

1.23

0.95 – 1.60

Males

White

1,007

44

15.89

11.82 – 21.35

2,769

1.0 (ref.)

–

African American

877

22

8.68

5.72 – 13.18

2,535

0.63

0.38 – 1.07

Asian

102

****

3.28

0.46 – 23.29

305

0.36

0.05 – 2.66

Hispanic

373

****

3.78

1.42 – 10.07

1,057

0.40

0.14 – 1.15

Native American

41

0

****

****

88

****

****

Other/ Multiple

176

****

11.12

5 – 24.75

540

0.81

0.34 – 1.93

*Race/ethnicity missing for 2043 females and 359 males
**IR: incidence rate, events per 1,000 patient-years
***HR: hazard ratio, adjusted for age, calendar year and region of the U.S.
****Cell size <11 suppressed per Centers for Medicare and Medicaid Services policies
Bold: confidence intervals are significant compared to White patients as reference group


Disclosure:

M. Barbhaiya,
None;

C. H. Feldman,
None;

J. M. Franklin,
None;

J. Liu,
None;

J. M. Foody,
None;

M. A. Fischer,
None;

D. H. Solomon,

Lilly, Amgen, CORRONA,

2,

Lilly, BMS, Novartis, Pfizer,

6,

Lilly, BMS, Novartis,

9;

K. H. Costenbader,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acute-myocardial-infarction-variation-among-u-s-medicaid-recipients-with-systemic-lupus-erythematosus-by-race-and-ethnicity-2000-2006/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology